Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer

HJ de Voogt; U Struder; Fritz Schröder; Jan Klijn; M de Pauw; R Sylvester

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer

HJ de Voogt, U Struder, Fritz Schröder, Jan Klijn, M de Pauw, R Sylvester

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	152-158
Number of pages	7
Journal	European Urology
Volume	33
Publication status	Published - 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{14fc19cf09ef4cb384f39ccc694a0650,

title = "Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer",

author = "{de Voogt}, HJ and U Struder and Fritz Schr{\"o}der and Jan Klijn and {de Pauw}, M and R Sylvester",

year = "1998",

language = "Undefined/Unknown",

volume = "33",

pages = "152--158",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

}

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. / de Voogt, HJ; Struder, U; Schröder, Fritz et al.

In: European Urology, Vol. 33, 1998, p. 152-158.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer

AU - de Voogt, HJ

AU - Struder, U

AU - Schröder, Fritz

AU - Klijn, Jan

AU - de Pauw, M

AU - Sylvester, R

PY - 1998

Y1 - 1998

M3 - Article

VL - 33

SP - 152

EP - 158

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -